Nymox Pharmaceutical Corp. (NYMX) just announced that results from its Phase 2 prostate cancer study demonstrated statistically significant better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.
Nymox Pharmaceutical has suddenly spiked to the upside on increased volume and is now up 0.64 at $1.63. The stock is challenging the upper end of a 2 1/2 week range.
For comments and feedback: editorial@rttnews.com